Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits.

Dermatol Pract Concept · 2025 · PMC12339055 · PMID 40790454

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Both IL-17i and IL-23i showed sustained efficacy after one year of follow-up; however, a comparison of the two cohorts revealed a difference in therapeutic maintenance showed a trend favoring IL-23i.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.